Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism
Type I pseudohypoaldosteronism (PHA1) is a rare form of mineralocorticoid resistance characterized by neonatal renal salt wasting and failure to thrive. Typical biochemical features include high levels of plasma aldosterone and renin, hyponatremia and hyperkalemia. Different mutations of the human m...
Gespeichert in:
Veröffentlicht in: | Molecular and cellular endocrinology 2004-03, Vol.217 (1), p.119-125 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 125 |
---|---|
container_issue | 1 |
container_start_page | 119 |
container_title | Molecular and cellular endocrinology |
container_volume | 217 |
creator | Sartorato, P Khaldi, Y Lapeyraque, A.-L Armanini, D Kuhnle, U Salomon, R Caprio, M Viengchareun, S Lombès, M Zennaro, M.-C |
description | Type I pseudohypoaldosteronism (PHA1) is a rare form of mineralocorticoid resistance characterized by neonatal renal salt wasting and failure to thrive. Typical biochemical features include high levels of plasma aldosterone and renin, hyponatremia and hyperkalemia. Different mutations of the human mineralocorticoid receptor (
hMR) gene have been identified in subjects affected by the autosomal dominant or sporadic form of the disease. Our laboratory has investigated a large number of subjects with familial and sporadic PHA1. Several different mutations have been detected, which are localized in different coding exons of the
hMR gene. These mutations either create truncated proteins, either affect specific amino acids involved in receptor function. In this paper, we review hMR mutations described to date in PHA1 and their functional characterization. We discuss the absence of mutations in some kindreds and the role of precise phenotypic and biological examination of patients to allow for identification of other genes potentially involved in the disease. |
doi_str_mv | 10.1016/j.mce.2003.10.017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71914250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303720703003897</els_id><sourcerecordid>71914250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-ade4f730459ed46a816d05c84a10c755263b3a346295d749a32ab1287abf1ade3</originalsourceid><addsrcrecordid>eNp9kE1rGzEQhkVpaJy0PyCXoFNv64y-Vmt6CiFtDYFc0ksvQpZmG5nd1VbSBvzvK2NDbj2NRjzvC_MQcsNgzYC1d_v16HDNAUTd18D0B7JineZNB0p_JCsQIBrNQV-Sq5z3AKAV7z6RS6aYkB2DFfm9nawr4c2WMP2h41LqI06Zxp6WV6RjmDDZIbqYSnAxeJrQ4VxiomGiL4cZ6ZbOGRcfXw9ztIOPuWCKU8jjZ3LR2yHjl_O8Jr--P748_Gyenn9sH-6fGieZKo31KHstQKoNetnajrUelOukZeC0UrwVO2GFbPlGeS03VnC7Y7zTdtezGhbX5Oupd07x74K5mDFkh8NgJ4xLNpptmOQKKshOoEsx54S9mVMYbToYBuYo1OxNFWqOQo9fVWjN3J7Ll92I_j1xNliBbycA64lvAZPJLuDk0Ieqqhgfw3_q_wEpgYeR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71914250</pqid></control><display><type>article</type><title>Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sartorato, P ; Khaldi, Y ; Lapeyraque, A.-L ; Armanini, D ; Kuhnle, U ; Salomon, R ; Caprio, M ; Viengchareun, S ; Lombès, M ; Zennaro, M.-C</creator><creatorcontrib>Sartorato, P ; Khaldi, Y ; Lapeyraque, A.-L ; Armanini, D ; Kuhnle, U ; Salomon, R ; Caprio, M ; Viengchareun, S ; Lombès, M ; Zennaro, M.-C</creatorcontrib><description>Type I pseudohypoaldosteronism (PHA1) is a rare form of mineralocorticoid resistance characterized by neonatal renal salt wasting and failure to thrive. Typical biochemical features include high levels of plasma aldosterone and renin, hyponatremia and hyperkalemia. Different mutations of the human mineralocorticoid receptor (
hMR) gene have been identified in subjects affected by the autosomal dominant or sporadic form of the disease. Our laboratory has investigated a large number of subjects with familial and sporadic PHA1. Several different mutations have been detected, which are localized in different coding exons of the
hMR gene. These mutations either create truncated proteins, either affect specific amino acids involved in receptor function. In this paper, we review hMR mutations described to date in PHA1 and their functional characterization. We discuss the absence of mutations in some kindreds and the role of precise phenotypic and biological examination of patients to allow for identification of other genes potentially involved in the disease.</description><identifier>ISSN: 0303-7207</identifier><identifier>EISSN: 1872-8057</identifier><identifier>DOI: 10.1016/j.mce.2003.10.017</identifier><identifier>PMID: 15134810</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Aldosterone ; Aldosterone - blood ; Exons - genetics ; Genes, Dominant - genetics ; Hormone resistance ; Humans ; Hypokalemia - genetics ; Hypokalemia - physiopathology ; Hyponatremia - genetics ; Hyponatremia - physiopathology ; Kidney - physiopathology ; Mineralocorticoids - metabolism ; Mutation ; Nuclear receptors ; Pedigree ; Predictive Value of Tests ; Pseudohypoaldosteronism - blood ; Pseudohypoaldosteronism - congenital ; Pseudohypoaldosteronism - genetics ; Pseudohypoaldosteronism - physiopathology ; Receptors, Mineralocorticoid - genetics ; Receptors, Mineralocorticoid - metabolism ; Renin - blood ; Salt loss ; Salts - metabolism ; Steroids</subject><ispartof>Molecular and cellular endocrinology, 2004-03, Vol.217 (1), p.119-125</ispartof><rights>2003 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-ade4f730459ed46a816d05c84a10c755263b3a346295d749a32ab1287abf1ade3</citedby><cites>FETCH-LOGICAL-c415t-ade4f730459ed46a816d05c84a10c755263b3a346295d749a32ab1287abf1ade3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0303720703003897$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15134810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sartorato, P</creatorcontrib><creatorcontrib>Khaldi, Y</creatorcontrib><creatorcontrib>Lapeyraque, A.-L</creatorcontrib><creatorcontrib>Armanini, D</creatorcontrib><creatorcontrib>Kuhnle, U</creatorcontrib><creatorcontrib>Salomon, R</creatorcontrib><creatorcontrib>Caprio, M</creatorcontrib><creatorcontrib>Viengchareun, S</creatorcontrib><creatorcontrib>Lombès, M</creatorcontrib><creatorcontrib>Zennaro, M.-C</creatorcontrib><title>Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism</title><title>Molecular and cellular endocrinology</title><addtitle>Mol Cell Endocrinol</addtitle><description>Type I pseudohypoaldosteronism (PHA1) is a rare form of mineralocorticoid resistance characterized by neonatal renal salt wasting and failure to thrive. Typical biochemical features include high levels of plasma aldosterone and renin, hyponatremia and hyperkalemia. Different mutations of the human mineralocorticoid receptor (
hMR) gene have been identified in subjects affected by the autosomal dominant or sporadic form of the disease. Our laboratory has investigated a large number of subjects with familial and sporadic PHA1. Several different mutations have been detected, which are localized in different coding exons of the
hMR gene. These mutations either create truncated proteins, either affect specific amino acids involved in receptor function. In this paper, we review hMR mutations described to date in PHA1 and their functional characterization. We discuss the absence of mutations in some kindreds and the role of precise phenotypic and biological examination of patients to allow for identification of other genes potentially involved in the disease.</description><subject>Aldosterone</subject><subject>Aldosterone - blood</subject><subject>Exons - genetics</subject><subject>Genes, Dominant - genetics</subject><subject>Hormone resistance</subject><subject>Humans</subject><subject>Hypokalemia - genetics</subject><subject>Hypokalemia - physiopathology</subject><subject>Hyponatremia - genetics</subject><subject>Hyponatremia - physiopathology</subject><subject>Kidney - physiopathology</subject><subject>Mineralocorticoids - metabolism</subject><subject>Mutation</subject><subject>Nuclear receptors</subject><subject>Pedigree</subject><subject>Predictive Value of Tests</subject><subject>Pseudohypoaldosteronism - blood</subject><subject>Pseudohypoaldosteronism - congenital</subject><subject>Pseudohypoaldosteronism - genetics</subject><subject>Pseudohypoaldosteronism - physiopathology</subject><subject>Receptors, Mineralocorticoid - genetics</subject><subject>Receptors, Mineralocorticoid - metabolism</subject><subject>Renin - blood</subject><subject>Salt loss</subject><subject>Salts - metabolism</subject><subject>Steroids</subject><issn>0303-7207</issn><issn>1872-8057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rGzEQhkVpaJy0PyCXoFNv64y-Vmt6CiFtDYFc0ksvQpZmG5nd1VbSBvzvK2NDbj2NRjzvC_MQcsNgzYC1d_v16HDNAUTd18D0B7JineZNB0p_JCsQIBrNQV-Sq5z3AKAV7z6RS6aYkB2DFfm9nawr4c2WMP2h41LqI06Zxp6WV6RjmDDZIbqYSnAxeJrQ4VxiomGiL4cZ6ZbOGRcfXw9ztIOPuWCKU8jjZ3LR2yHjl_O8Jr--P748_Gyenn9sH-6fGieZKo31KHstQKoNetnajrUelOukZeC0UrwVO2GFbPlGeS03VnC7Y7zTdtezGhbX5Oupd07x74K5mDFkh8NgJ4xLNpptmOQKKshOoEsx54S9mVMYbToYBuYo1OxNFWqOQo9fVWjN3J7Ll92I_j1xNliBbycA64lvAZPJLuDk0Ieqqhgfw3_q_wEpgYeR</recordid><startdate>20040331</startdate><enddate>20040331</enddate><creator>Sartorato, P</creator><creator>Khaldi, Y</creator><creator>Lapeyraque, A.-L</creator><creator>Armanini, D</creator><creator>Kuhnle, U</creator><creator>Salomon, R</creator><creator>Caprio, M</creator><creator>Viengchareun, S</creator><creator>Lombès, M</creator><creator>Zennaro, M.-C</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040331</creationdate><title>Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism</title><author>Sartorato, P ; Khaldi, Y ; Lapeyraque, A.-L ; Armanini, D ; Kuhnle, U ; Salomon, R ; Caprio, M ; Viengchareun, S ; Lombès, M ; Zennaro, M.-C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-ade4f730459ed46a816d05c84a10c755263b3a346295d749a32ab1287abf1ade3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aldosterone</topic><topic>Aldosterone - blood</topic><topic>Exons - genetics</topic><topic>Genes, Dominant - genetics</topic><topic>Hormone resistance</topic><topic>Humans</topic><topic>Hypokalemia - genetics</topic><topic>Hypokalemia - physiopathology</topic><topic>Hyponatremia - genetics</topic><topic>Hyponatremia - physiopathology</topic><topic>Kidney - physiopathology</topic><topic>Mineralocorticoids - metabolism</topic><topic>Mutation</topic><topic>Nuclear receptors</topic><topic>Pedigree</topic><topic>Predictive Value of Tests</topic><topic>Pseudohypoaldosteronism - blood</topic><topic>Pseudohypoaldosteronism - congenital</topic><topic>Pseudohypoaldosteronism - genetics</topic><topic>Pseudohypoaldosteronism - physiopathology</topic><topic>Receptors, Mineralocorticoid - genetics</topic><topic>Receptors, Mineralocorticoid - metabolism</topic><topic>Renin - blood</topic><topic>Salt loss</topic><topic>Salts - metabolism</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sartorato, P</creatorcontrib><creatorcontrib>Khaldi, Y</creatorcontrib><creatorcontrib>Lapeyraque, A.-L</creatorcontrib><creatorcontrib>Armanini, D</creatorcontrib><creatorcontrib>Kuhnle, U</creatorcontrib><creatorcontrib>Salomon, R</creatorcontrib><creatorcontrib>Caprio, M</creatorcontrib><creatorcontrib>Viengchareun, S</creatorcontrib><creatorcontrib>Lombès, M</creatorcontrib><creatorcontrib>Zennaro, M.-C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular and cellular endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sartorato, P</au><au>Khaldi, Y</au><au>Lapeyraque, A.-L</au><au>Armanini, D</au><au>Kuhnle, U</au><au>Salomon, R</au><au>Caprio, M</au><au>Viengchareun, S</au><au>Lombès, M</au><au>Zennaro, M.-C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism</atitle><jtitle>Molecular and cellular endocrinology</jtitle><addtitle>Mol Cell Endocrinol</addtitle><date>2004-03-31</date><risdate>2004</risdate><volume>217</volume><issue>1</issue><spage>119</spage><epage>125</epage><pages>119-125</pages><issn>0303-7207</issn><eissn>1872-8057</eissn><abstract>Type I pseudohypoaldosteronism (PHA1) is a rare form of mineralocorticoid resistance characterized by neonatal renal salt wasting and failure to thrive. Typical biochemical features include high levels of plasma aldosterone and renin, hyponatremia and hyperkalemia. Different mutations of the human mineralocorticoid receptor (
hMR) gene have been identified in subjects affected by the autosomal dominant or sporadic form of the disease. Our laboratory has investigated a large number of subjects with familial and sporadic PHA1. Several different mutations have been detected, which are localized in different coding exons of the
hMR gene. These mutations either create truncated proteins, either affect specific amino acids involved in receptor function. In this paper, we review hMR mutations described to date in PHA1 and their functional characterization. We discuss the absence of mutations in some kindreds and the role of precise phenotypic and biological examination of patients to allow for identification of other genes potentially involved in the disease.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>15134810</pmid><doi>10.1016/j.mce.2003.10.017</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0303-7207 |
ispartof | Molecular and cellular endocrinology, 2004-03, Vol.217 (1), p.119-125 |
issn | 0303-7207 1872-8057 |
language | eng |
recordid | cdi_proquest_miscellaneous_71914250 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Aldosterone Aldosterone - blood Exons - genetics Genes, Dominant - genetics Hormone resistance Humans Hypokalemia - genetics Hypokalemia - physiopathology Hyponatremia - genetics Hyponatremia - physiopathology Kidney - physiopathology Mineralocorticoids - metabolism Mutation Nuclear receptors Pedigree Predictive Value of Tests Pseudohypoaldosteronism - blood Pseudohypoaldosteronism - congenital Pseudohypoaldosteronism - genetics Pseudohypoaldosteronism - physiopathology Receptors, Mineralocorticoid - genetics Receptors, Mineralocorticoid - metabolism Renin - blood Salt loss Salts - metabolism Steroids |
title | Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T14%3A47%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inactivating%20mutations%20of%20the%20mineralocorticoid%20receptor%20in%20Type%20I%20pseudohypoaldosteronism&rft.jtitle=Molecular%20and%20cellular%20endocrinology&rft.au=Sartorato,%20P&rft.date=2004-03-31&rft.volume=217&rft.issue=1&rft.spage=119&rft.epage=125&rft.pages=119-125&rft.issn=0303-7207&rft.eissn=1872-8057&rft_id=info:doi/10.1016/j.mce.2003.10.017&rft_dat=%3Cproquest_cross%3E71914250%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71914250&rft_id=info:pmid/15134810&rft_els_id=S0303720703003897&rfr_iscdi=true |